Accessibility Menu
Vitrolife Ab (publ) logo

Vitrolife Ab (publ)(OTC) VTRLY

Market Cap$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-17%
5 Year-62%
1 Year-36%
1 Month+0%
$9.50
+0.00%
+0.00Today
Vitrolife Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 9.502026-08-13
Vitrolife Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 9.502026-08-06
1 month+0%USD 9.502026-07-09
3 month-13.64%USD 11.002026-05-15
Year to date-36.26%USD 14.902025-12-29
1 year-35.89%USD 14.822025-08-12
3 year-54.72%USD 20.982023-07-18
5 year-61.66%USD 24.782021-02-04
Since inception-17.28%USD 11.482016-08-10

Vitrolife Ab (publ) Financials at a Glance

Market Cap

$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 3.38B

Net Income (TTM)

-SEK 4.98B

EPS (TTM)

-$3.91

P/E Ratio

-2.43

Dividend

$0.12

Beta (Volatility)

0.07 (Low)

Price

$9.50

Volume

569

Open

$9.50

Previous Close

$9.50

Daily Range

$9.50 - $9.50

52-Week Range

$9.50 - $18.55

Estimated Earnings Date

Apr 22, 2026

VTRLY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vitrolife Ab (publ)

Vitrolife AB (publ) is a Swedish medical technology company specializing in products for assisted reproductive technologies (ART). Established in 1994 and headquartered in Gothenburg, the company offers a comprehensive range of tools and solutions for in vitro fertilization (IVF) and related laboratory processes.

Products and Services
  • IVF culture media and oils for embryo development
  • Micromanipulation pipettes and laboratory equipment
  • Advanced time-lapse systems for embryo monitoring
Growth Outlook
  • Revenue increased to SEK 857 million in Q2 2026, up from SEK 807 million in Q1 2026
  • Operating income improved to SEK 198 million in Q2 2026, reflecting operational efficiency
  • Strong demand for ART products supports long-term growth potential
Financial Highlights
  • Net income of SEK 129 million reported in Q2 2026
  • Gross profit margin of 60.3% in Q2 2026, indicating strong profitability
  • Cash and cash equivalents totaled SEK 823 million as of June 30, 2026
Vitrolife AB (publ) operates in a growing market driven by increasing demand for fertility treatments. The company's innovative product offerings, including advanced time-lapse systems and IVF culture media, position it well within the assisted reproductive technology sector. Recent financial performance shows a positive trend, with significant revenue growth and improved operating income, reflecting effective management and operational efficiencies. The strong gross profit margin further underscores the company's ability to maintain profitability while expanding its market presence. With a solid cash position, Vitrolife is well-equipped to invest in future growth opportunities and continue delivering value to its stakeholders.
AI Generated • Aug 11, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,103

CEO

Bronwyn Brophy O'Connor

Website

www.vitrolife.com

Headquarters

Gothenburg, VG 421 32, SE

VTRLY Financials

Key Financial Metrics (TTM)

Gross Margin

53.72%

Operating Margin

19.50%

Net Income Margin

-146.96%

Return on Equity

-53.29%

Return on Capital

6.10%

Return on Assets

-44.08%

Earnings Yield

-41.15%

Dividend Yield

1.24%

Payout Ratio

-2.99%

Stock Overview

Market Cap

$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

135.42M

Volume

569

Avg. Volume

32.032

Financials (TTM)

Gross Profit

SEK 1.94B

Operating Income

-SEK 4.77B

EBITDA

-SEK 4.54B

Operating Cash Flow

SEK 720.19M

Capital Expenditure

-SEK 115.00M

Free Cash Flow

SEK 605.33M

Cash & ST Invst.

SEK 823.00M

Total Debt

SEK 1.60B

Vitrolife Ab (publ) Performance Analysis

Vitrolife Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 319,568,58363.2%
20232023-12-31SEK 330,823,1483.5%
20242024-12-31SEK 341,349,8403.2%
20252025-12-31SEK 350,751,6572.8%
Vitrolife Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5.5%
Q42025-12-318.3%
Q12026-03-31-9.4%
Q22026-06-306.2%
Vitrolife Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK 0.29-17.0%
20232023-12-31SEK -2.68N/A
20242024-12-31SEK 0.36N/A
20252025-12-31SEK -3.77N/A
Vitrolife Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31-5402.7%
Q12026-03-31101.9%
Q22026-06-3028.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 857.00M

-1.6%

Gross Profit

SEK 517.00M

+2.4%

Gross Margin

60.33%

N/A

Market Cap

$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.12M

N/A

Employees

1,151

N/A

Net Income

SEK 129.00M

+29.0%

EBITDA

SEK 258.00M

+74.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 823.00M

-10.6%

Total Debt

SEK 1.60B

-19.7%

Accounts Receivable

SEK 909.00M

+18.2%

Inventory

SEK 440.00M

+2.3%

Long Term Debt

SEK 1.56B

-15.4%

Short Term Debt

SEK 45.00M

-70.6%

Return on Assets

-44.08%

N/A

Return on Invested Capital

6.18%

N/A

Free Cash Flow

SEK 106.00M

-24.8%

Operating Cash Flow

SEK 140.00M

-7.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HTSUFHisamitsu Pharmaceutical Co., Inc.
$29.00+0.00%
GNNDYGN Store Nord A/S
$47.35+2.17%
BRCTFBioArctic AB (publ)
$31.78+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About VTRLY

What is the current price of Vitrolife Ab (publ)?

Vitrolife Ab (publ) is trading at $9.50 per share.

What is the 52-week range for Vitrolife Ab (publ)?

Over the past 52 weeks, Vitrolife Ab (publ) has traded between $9.50 and $18.55.

How much debt does Vitrolife Ab (publ) have?

As of the most recent reporting period, Vitrolife Ab (publ) reported total debt of SEK 165.42M.

How much cash does Vitrolife Ab (publ) have on hand?

Vitrolife Ab (publ) reported SEK 85.04M in cash and cash equivalents in its most recent financial results.

What is Vitrolife Ab (publ)’s dividend yield?

Vitrolife Ab (publ) currently has a dividend yield of 1.24%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services